Skip to content
Victoza(liraglutide)
Saxenda, Victoza, Xultophy (liraglutide) is a protein pharmaceutical. Liraglutide was first approved as Victoza on 2009-06-30. It has been approved in Europe to treat obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
diagnosisD003933
physiological phenomenaD010829
Trade Name
FDA
EMA
Saxenda, Victoza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Liraglutide recombinant
Tradename
Company
Number
Date
Products
SAXENDAKazia TherapeuticsN-206321 RX2014-12-23
1 products, RLD, RS
VICTOZANovo NordiskN-022341 RX2010-01-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
saxendaNew Drug Application2022-01-10
victozaNew Drug Application2023-02-06
xultophy 100/3.6Biologic Licensing Application2019-11-15
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
LIRAGLUTIDE RECOMBINANT, SAXENDA, NOVO
2023-12-04NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Liraglutide Recombinant, Saxenda, Novo
99686592037-01-09U-2313, U-2438
91322392032-02-01DP
94571542027-09-27DP
96876112027-02-27DP
RE463632026-08-03DP
89203832026-07-17DP
97759532026-07-17DP
102201552026-07-17DP
110970632026-07-17DP
91080022026-01-26DP
96161802026-01-20DP
98617572026-01-20DP
103576162026-01-20DP
103766522026-01-20DP
113116792026-01-20DP
86849692025-10-20DP
114464432025-10-20DP
81148332025-08-13DS, DP
77629942024-05-23DP
85798692023-06-30DP
Liraglutide Recombinant, Victoza, Novo Nordisk Inc
92658932032-09-23DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AE: Insulins and analogues for injection, long-acting
— A10AE56: Insulin degludec and liraglutide
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ02: Liraglutide
HCPCS
No data
Clinical
Clinical Trials
412 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E112727645535206
ObesityD009765EFO_0001073E66.9101219321487
Type 1 diabetes mellitusD003922EFO_0001359E10614143335
Healthy volunteers/patients—20——3—23
OverweightD050177E66.31128618
Diabetes mellitusD003920EFO_0000400E08-E133122—7
Cardiovascular diseasesD002318EFO_0000319I98——2417
Metabolic syndromeD024821EFO_0000195E88.81——15—6
Weight lossD015431HP_0001824——23—5
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—212—5
Show 32 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nutrition disordersD009748EFO_0001069728—118
Glucose intoleranceD018149HP_0000833R73.03—11——2
Bipolar disorderD001714EFO_0000289F30.9—11——2
Obstructive sleep apneaD020181EFO_0003918G47.33——1—12
HyperglycemiaD006943HP_0003074R73.9——1—12
Binge-eating disorderD056912F50.2——1——1
Major depressive disorderD003865EFO_0003761F22——1——1
Endometrial hyperplasiaD004714N85.0—11——1
Brain deathD001926G93.82——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50—2——24
PsoriasisD011565EFO_0000676L40—1——23
Pediatric obesityD063766—1——12
Alzheimer diseaseD000544EFO_0000249F03—1——12
Diabetic neuropathiesD003929EFO_1000783—1——12
Renal dialysisD006435EFO_0010690Z99.2—1———1
Opioid-related disordersD009293EFO_0005611F1111———1
Opiate substitution treatmentD05885011———1
Body weightD001835EFO_0004338—1———1
Smoking cessationD016540EFO_0004319—1———1
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD0072491————1
DementiaD003704F031————1
Therapeutic equivalencyD0138101————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ischemic strokeD000083242————11
Transient ischemic attackD002546EFO_0003764G45.9————11
St elevation myocardial infarctionD000072657————11
Inferior wall myocardial infarctionD056989EFO_1000983————11
Female infertilityD007247EFO_0008560N97————11
RecurrenceD012008————11
Cognitive dysfunctionD060825G31.84————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLIRAGLUTIDE
INNliraglutide
Description
Liraglutide is a lipopeptide that is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a glucagon-like peptide-1 receptor agonist and a neuroprotective agent. It is a lipopeptide and a polypeptide.
Classification
Protein
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O
Identifiers
PDB—
CAS-ID204656-20-2
RxCUI475968
ChEMBL IDCHEMBL4524066
ChEBI ID—
PubChem CID16134956
DrugBankDB06655
UNII ID839I73S42A (ChemIDplus, GSRS)
Target
Agency Approved
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Saxenda - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Xultophy - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Victoza - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,238 documents
View more details
Safety
Black-box Warning
Black-box warning for: Saxenda, Victoza, Xultophy 100/3.6
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
382 adverse events reported
View more details